
Docetaxel trihydrate NEW
Price | $46 |
Package | 100mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2025-04-30 |
Product Details
Product Name: Docetaxel trihydrate | CAS No.: 148408-66-6 |
Purity: 99.74% | Supply Ability: 10g |
Release date: 2025/04/30 |
Product Introduction
Bioactivity
Name | Docetaxel trihydrate |
Description | Docetaxel trihydrate (RP-56976 Trihydrate) is an antineoplastic agent that has a unique mechanism of action as an inhibitor of cellular mitosis and that currently plays a central role in the therapy of many solid tumor including breast and lung cancer. Therapy with docetaxel has been associated with a low rate of serum enzyme elevations and rarely to instances of acute hepatic necrosis generally due to severe hypersensitivity reactions or sepsis. |
Cell Research | 2000 cells in 180 μL of medium are seeded in a 96-well plate, and 20 μL of drug solution is simultaneously added in triplicate to each well. The plate is incubated for 3 days at 37°C in a humidified atmosphere of 5% CO2. On day 3, 25 μL of MTT reagent is added to each well. After 4 h of incubation, the medium is removed by aspiration. 0.2 mL of dimethylsulphoxide (DMSO) is added to each well and thoroughly mixed by using a mechanical plate mixer to dissolve the resulting MTT-formazan crystals. Absorbance at 540 nm (OD) is measured by a reader. (Only for Reference) |
In vitro | Administering 33 mg/kg of Docetaxel every four days for three doses resulted in a 19.3-day growth delay in M2OL2 colorectal cancer xenografts. Docetaxel exhibited potent antitumor activity in MX-1, SK-MEL-2, LX-1, and OVCAR-3 xenograft models. Biweekly administration of Docetaxel over 14 days suppressed fibroblast growth factor 2-mediated angiogenesis with an IC50 of 5.4 mg/kg. A dose of 10 mg/kg Docetaxel completely inhibited angiogenesis in mice. |
In vivo | Docetaxel inhibits the clonogenic survival of various human cancer cell lines including Hs746T (stomach), AGS (stomach), HeLa (cervical), CaSki (cervical), BxPC3 (pancreatic), and Capan-1 (pancreatic) with IC50 values of 1 nM for the stomach, and 0.3 nM for the others, respectively. Additionally, Docetaxel suppresses the chemotaxis of human umbilical vein endothelial cells stimulated by angiogenic factors, thymidine phosphorylase, or VEGF, with an IC50 of 10 pM. Moreover, Docetaxel induces the expression of Prostaglandin H Synthase-2 (PGHS-2) in human monocytes without affecting its expression in RAW 264.7 mouse macrophages. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 100 mg/mL (116.02 mM), Sonication is recommended. DMSO : 100 mg/mL (116.02 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) |
Keywords | Tubulin β-1 chain | RP56976 (NSC 628503) | RP-56976 | RP56976 | RP 56976 | MicrotubuleAssociated | Microtubule/Tubulin | Microtubule Associated | Inhibitor | inhibit | Docetaxel trihydrate | Docetaxel Trihydrate | Docetaxel | Bcl-2 | Apoptosis |
Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | L-Glutamic acid | Metronidazole | Tributyrin | L-Ascorbic acid sodium salt | Salicylic acid |
Related Compound Libraries | Bioactive Compound Library | Alkaloid Natural Product Library | EMA Approved Drug Library | Selected Plant-Sourced Compound Library | Anti-Cancer Clinical Compound Library | Microtubule-Targeted Compound Library | Natural Product Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$46.00/100mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-04-30 | |
$46.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-04-28 | |
$0.00/1KG |
VIP1Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-17 | |
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-12 | |
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
$1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-15 | |
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-08 |
- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY